Origin Genomics founder Cathy Tie told Wired that the ability to edit the DNA of human embryos should be treated as a "moral imperative" if it can stop children from inheriting fatal genetic disorders.
Why Tie sees a duty to intervene
Tie argues that the technology now exists to correct mutations that cause conditions such as cystic fibrosis, Duchenne muscular dystrophy and sickle‑cell disease before a child is born. She says the alternative – allowing families to risk passing on known, treatable genes – is ethically indefensible.
"If we have the tools to prevent a child from suffering a fatal disease, we have a moral duty to use them," Tie said, adding that the same logic underpins vaccination programmes and prenatal screening.
Scientific promise and remaining hurdles
CRISPR‑Cas9, the gene‑editing system that Tie’s company commercialises, can cut DNA at a precise location and replace a faulty segment with a healthy copy. In animal models the technique has eliminated disease‑causing mutations without off‑target effects, and early‑stage human embryo trials in China and the United States have shown modest success rates.
Nevertheless, experts caution that editing embryos remains fraught with technical uncertainty. Unintended edits, mosaicism – where only some cells carry the correction – and long‑term health impacts are still under investigation, according to a review published in *Nature* earlier this year.
Regulation and ethical push‑back
In the United States, the Food and Drug Administration currently bars clinical use of germline editing, limiting research to pre‑implantation studies that cannot result in a pregnancy. Europe’s European Medicines Agency has issued similar prohibitions, while China’s Ministry of Science and Technology requires explicit government approval for any embryo‑editing work.
Opposition groups, including several religious organisations and bioethicists, argue that altering the human germline crosses an irreversible line. They warn of a slippery slope toward designer babies and stress the importance of societal consensus before any therapy reaches clinics.
Tie counters that the debate has been skewed by the 2018 case of Chinese scientist He Jiankui, whose unauthorised edits to twin embryos sparked worldwide condemnation. She says responsible, transparent research – overseen by independent ethics boards – can separate legitimate therapeutic goals from speculative enhancement.
Potential impact if policies shift
Should regulatory frameworks evolve to permit therapeutic germline editing, millions of families could avoid the burden of hereditary disease. Modelling by the World Health Organization estimates that eliminating just five common monogenic disorders could reduce global child mortality by up to 0.5 per cent.
Origin Genomics plans to launch a Phase 1 clinical trial in 2028, targeting embryos carrying the most prevalent cystic fibrosis mutation in the United Kingdom. The company says it will enrol only couples who have undergone extensive genetic counselling and who meet strict safety criteria.
Public opinion remains divided. A Pew Research Centre survey released last month found that 54 % of respondents in the United States support embryo editing to prevent serious disease, while 31 % oppose it on moral grounds. In the United Kingdom, a similar poll showed a narrower margin of support, reflecting lingering concerns about long‑term societal effects.
As the science advances, the conversation is likely to shift from “if” to “how”. Tie believes that waiting for an ideal safety profile could deny children a disease‑free start, and urges policymakers to develop clear, evidence‑based guidelines that balance innovation with precaution.
Discussion (0)
Sign in to join the discussion.